Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Breast Cancer HER2+ (Sep 2019)

Posted by Matt Breese on Sep 6, 2019

Find me on:

According to our recent payer coverage analysis for breast cancer (HER2+) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for breast cancer (HER2+) treatments shows that under the pharmacy benefit, about 32% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Breast Cancer_HER2+_2Q2019Data snapshot as of Q3 2019

Trends: In July 2019, Amgen Inc. and Allergan plc launched oncology drugs Mvasi
(bevacizumab-awwb), an Avastin (bevacizumab) biosimilar, and Kanjinti (trastuzumab), a Herceptin (trastuzumab) biosimilar.    

To read the full Reality Check on Breast Cancer (HER2+) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing